LLY News and Press, Eli Lilly and Company From 03/26/24

2024-03-26 11:43:00 ET More on CRISPR Technology Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript) Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript) Editas Medicine, Inc. (EDIT...

2024-03-26 07:37:54 ET More on Viking Therapeutics Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront Viking Therapeutics: Here To Stay In Obesity, Or A Flash In The Pan? Viking Therapeutics: VK2735 Data Supports A Buyout Jefferies start...

2024-03-26 05:51:00 ET Some investors might remember the obesity drugs developed by Arena Pharmaceuticals and Vivus Pharmaceuticals several years ago. They'll probably also recall that the initial euphoria over those drugs quickly faded. This time it's different. The commercial success ...

2024-03-25 16:00:50 ET Summary T. Rowe Price Dividend Growth ETF is an actively managed fund with selection criteria based on dividend growth, quality and valuation. The TDVG ETF is close to the S&P 500 regarding valuation, inferior in earnings growth, and superior in quality....

2024-03-25 13:07:32 ET Summary M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot ...

2024-03-25 06:25:00 ET One of the biggest themes in the pharmaceutical market right now is weight-loss treatments. Demand is off the charts for medications including Ozempic, Rybelsus, Saxenda, Wegovy, Mounjaro, Jardiance, and Zepbound. That's a long list of treatments, isn't it? What y...

2024-03-25 02:07:51 ET Summary Sanofi has underperformed the U.S. stock market lately but now offers one of the smartest growth-at-a-reasonable-price setups in Big Pharma. Sanofi is best known for its patented drug Dupixent and numerous vaccines manufactured for global use, which ...

2024-03-24 23:25:36 ET Summary The rate of rise for big-cap tech stocks is slowing down or losing altitude, suggesting it may not be the best time to invest in them. The economy is growing, inflation is under control, and the Fed is committed to cutting rates, creating opportuniti...

2024-03-23 07:52:56 ET Summary PureTech Health's founded entity, Karuna Therapeutics, has been successful in developing a therapeutic with an optimized profile. Karuna Therapeutics was acquired by BMY for $14 billion. PureTech's lead asset, LYT-100, may be a promising treatmen...

2024-03-23 05:50:46 ET Summary Eli Lilly's stock price has increased by 129% in a year, with a Forward Price-To-Earnings Ratio of 60.4. Lilly's valuation in a base case scenario at $171/share, considering traditional drug revenues. New growth markets, such as obesity, Alzheime...